Azathioprine: Clinical Guide
Indications
Azathioprine is indicated for renal transplantation (preventing rejection) and rheumatoid arthritis, with extensive off-label use in autoimmune disorders including inflammatory bowel disease, autoimmune hepatitis, immunobullous diseases, atopic dermatitis, and other dermatological conditions 1, 2.
The starting dose is 1-3 mg/kg daily for transplantation and 1.0 mg/kg daily (50-100 mg) for rheumatoid arthritis, with potential increases up to 2.5 mg/kg daily if needed 1. Therapeutic effects typically require 6-8 weeks minimum, with an adequate trial being 12 weeks 1.
Mechanism of Action
Azathioprine is a synthetic purine analog derived from 6-mercaptopurine that acts as a purine antagonist 3. Its active metabolites disrupt endogenous purine function, producing both cytotoxic and immunosuppressive effects by interfering with DNA synthesis and cellular proliferation 4, 3.
Absolute Contraindications
The following are absolute contraindications 2:
- Hypersensitivity to azathioprine or 6-mercaptopurine
- Severe infections
- Severely impaired hepatic or bone marrow function
- Pancreatitis
- Live vaccines
- Patients with absent TPMT activity (TPMT null) should generally NOT receive azathioprine due to very high risk of profound neutropenia 2
Relative contraindications include pregnancy (unless benefits outweigh risks), lactation, and known malignancy 2.
Side Effects
Hematologic (Most Serious)
- Leukopenia occurs in >50% of transplant patients and 28% of rheumatoid arthritis patients 1
- Severe leukopenia (<2500 cells/mm³) in 16% of transplant recipients and 5.3% of RA patients 1
- Thrombocytopenia, anemia (including macrocytic anemia), and bleeding 1
- Patients with low/absent TPMT or NUDT15 activity face severe, life-threatening myelosuppression risk 1
Gastrointestinal
- Nausea and vomiting in approximately 12% of patients, often dose-dependent 1
- Can be minimized by divided dosing, taking with meals, or gradual dose escalation 2
- Diarrhea, abdominal pain
- Hypersensitivity pancreatitis (rare but serious) 1
Hepatotoxicity
- Elevated alkaline phosphatase, bilirubin, and transaminases 1
- Rare but life-threatening hepatic veno-occlusive disease with chronic use 1
- Most common within 6 months of transplantation, generally reversible with drug interruption 1
Malignancy Risk
- Lymphoma risk: 0.5% in transplant recipients 1
- Other neoplasias: 2.8% in transplant recipients 1
- Increased risk of Epstein-Barr-positive lymphoma (11/12 patients in one study) 2
Other
- Skin rashes, alopecia, fever, arthralgias 1
- Infections (20% in transplant recipients, <1% in RA) 1
- Reversible interstitial pneumonitis 1
- Hepatosplenic T-cell lymphoma 1
Critical Precautions for Long-Term Treatment
1. Mandatory TPMT Testing Before Initiation
TPMT activity MUST be checked in all patients prior to receiving azathioprine 2. This is a Strength A recommendation with level 1+ evidence.
- Normal TPMT activity: Use conventional doses (low risk of profound neutropenia) 2
- Intermediate/heterozygous TPMT activity: Reduce maintenance dose significantly 2
- Absent TPMT activity: Generally do NOT prescribe azathioprine 2
- Consider NUDT15 genotyping in patients with severe myelosuppression 1
2. Blood Monitoring Schedule
Complete blood counts with platelet counts 1:
- Weekly during first month
- Twice monthly for months 2-3
- Monthly thereafter or more frequently with dose changes
Periodic liver function tests (transaminases, alkaline phosphatase, bilirubin) for early hepatotoxicity detection 1.
3. Malignancy Risk Management
The best approach is to restrict azathioprine courses to short-to-medium term 2. For patients requiring long-term treatment without alternatives:
- Counsel about possible malignancy risk (likely small in absolute terms) 2
- Rigorous photoprotection is highly important - UV exposure significantly increases carcinogenic risk in thiopurine-treated patients 2
- Regular skin cancer surveillance, especially in transplant recipients with multiple dysplastic keratoses 2
4. Drug Interactions Requiring Dose Adjustment
With Xanthine Oxidase Inhibitors (Allopurinol/Febuxostat):
- Reduce azathioprine to approximately 1/3 to 1/4 usual dose when combined with allopurinol 1
- Concomitant use with febuxostat is NOT recommended 1
- XO inhibition increases plasma concentrations of azathioprine/6-MP, causing toxicity 1
With Ribavirin:
- Severe pancytopenia risk - monitor CBC weekly initially 1
With Aminosalicylates:
- Use with caution (inhibit TPMT enzyme) 1
With Warfarin:
- May inhibit anticoagulant effect 1
5. Special Populations
Renal Dysfunction:
- Use lower doses, especially in oliguric patients with tubular necrosis 1
Elderly/Hepatic Impairment:
- Doses at lower end of range recommended 2
Pregnancy/Lactation:
6. Duration of Treatment
Maintenance therapy should be at lowest effective dose 1. While optimal duration is undetermined, discontinuation rates are approximately 15% in the first year, primarily due to intolerance 5. For patients with clinical response, azathioprine can be continued long-term with careful monitoring and gradual dose reduction attempts (0.5 mg/kg or ~25 mg decrements every 4 weeks) 1.
Evidence supports continuous long-term use when effective and tolerated - withdrawal substantially increases relapse risk in inflammatory bowel disease 6. The benefit/risk ratio remains favorable long-term despite lymphoma risk 6.
Key Clinical Pitfalls
- Never skip TPMT testing - this single test prevents life-threatening myelosuppression
- Do not increase doses to toxic levels even for threatened rejection 1
- Delayed drug effects - therapeutic response and toxicity may persist weeks after dose changes due to active metabolite persistence 2
- If hepatic veno-occlusive disease suspected, permanently withdraw azathioprine 1
- Discontinuation rate ~15% in first year, mainly from GI intolerance (nausea/vomiting) 5